News

AIN Ventures and VIPC Invest in Cerbrec to Accelerate AI Innovation

Cerbrec, a leading Virginia-based AI platform provider, announced that AIN Ventures has invested in its seed funding round. This investment will enable Cerbrec to accelerate its mission of equipping biotech and pharmaceutical companies, along with those in other industries, with cutting-edge tools for creating tailored AI solutions.

Cerbrec’s flagship product, Graphbook, is an innovative drag-and-drop AI platform that allows subject matter experts to design advanced, customized AI solutions without the need for coding or prior AI development experience. Graphbook effectively tackles critical challenges in AI development, such as reducing technical barriers, shortening time to delivery, and improving AI transparency for review and documentation, all while ensuring compliance with regulations.

“We are redefining the AI development process by empowering everyone to create bespoke AI solutions using natural language or drag-and-drop,” said Garrett Wang, CEO of Cerbrec. “This new funding allows us to enhance our platform and expand its reach across biotech, pharma, higher education, and beyond. We are excited to partner with investors who share our passion for pushing the boundaries of AI and are grateful for the support that will help us make a lasting impact on both the AI landscape and the broader technology ecosystem.”

Cerbrec stands out in the AI landscape due to its intuitive visual programming interface while also accepting natural language queries. This combination lets non-coder users without prior AI development experience easily design complex AI workflows, and organizations quickly create and deploy AI solutions that are tailored to their specific needs and use cases. Furthermore, Cerbrec prioritizes AI model transparency, auditability, and regulatory compliance with its solution.

Seed funding will be strategically allocated to expand the Cerbrec team, focusing on engineering and customer success roles, speeding up product development and feature enhancements for Graphbook, and scaling go-to-market efforts in the biotech and pharmaceutical sectors.

“Cerbrec’s approach to AI development is truly transformative. By putting the power of AI development directly into the hands of domain experts, they are unlocking the potential for innovation across many industries,” said Sherman Williams, Co-Founder and Managing Partner of AIN Ventures.

AIN Ventures’ investment in Cerbrec was carried out in collaboration with Virginia Innovation Partnership Corporation (VIPC)’s Virginia Venture Partners (VVP) and its Virginia Invests fund of funds initiative. Launched in 2024, Virginia Invests has taken LP positions in six fund managers, including AIN Ventures, to accelerate the infusion of capital into Virginia startups and generate new opportunities for Virginia entrepreneurs to grow and innovate. The program, powered by the U.S. Department of Treasury State Small Business Credit Initiative (SSBCI), is designed to catalyze over $250 million in investments over the next 3-5 years.

“AIN Ventures and VIPC share a unified commitment to advancing innovation and driving economic growth in Virginia by strategically focusing on emerging technologies and empowering visionary entrepreneurs to bring transformative ideas to life,” said Aurelia Flores, Director of the Virginia Invests program. “This investment into Cerbrec is a prime example of how the Virginia Invests program is helping fuel the growth of pioneering startups. We are proud to partner with AIN Ventures in this exciting journey, reinforcing Virginia’s role as a leader in innovation and creating an environment where startups like Cerbrec can thrive.”

Joining AIN Ventures in Cerbrec’s funding round are SRI International, Inner Loop Capital, Gurtin Ventures, among others, underscoring strong investor confidence in Cerbrec’s vision. Cerbrec is also part of the AWS Generative AI accelerator and Techstars Boston.

 

Read more here.

Recent News

07/01/2025

ISOThrive Announces Promising Phase 2 Interim Data for Novel Heartburn Treatment and Appoints Pharma Veteran Mike Walther as Chief Strategy Officer

ISOThrive Inc., a clinical-stage biopharmaceutical company, announced interim results from a Phase 2 study of its lead candidate, ISOT-101, for treatment of Non-Erosive Reflux Disease (NERD). The data showed positive trends in addressing heartburn frequency and symptom severity among proton pump inhibitor (PPI) partial-responders (PR), a patient population with major unmet medical need. These positive

07/01/2025

Gary Lowenthal Joins Focused Ultrasound Foundation’s Council

The Focused Ultrasound Foundation is pleased to welcome Gary Lowenthal to its Council, a dedicated group of goodwill ambassadors who work closely with the Board of Directors and staff to provide advice and assist with raising funds and building awareness. Mr. Lowenthal is a retired educator, entrepreneur, and executive with a career spanning education, international service,

06/25/2025

Liquet Medical Closes Oversubscribed Seed Round to Launch Pilot Study Evaluating Real-Time Hemodynamic Monitoring

Liquet Medical, a clinical-stage medical device company developing the Versus™ Catheter — a first-of-its-kind dual-tipped catheter system cleared by the FDA for controlled and selective infusion of fluids into the pulmonary vasculature and hemodynamic monitoring — announced the successful and oversubscribed close of its Seed funding round, which officially closed in May 2025. The capital